Hire

Kernal Bio adds IFLI backing and two hires to push in vivo CAR-T toward clinic

What's the deal? Kernal Bio has secured a strategic investment from the Institute for Follicular Lymphoma Innovation (IFLI)Dealroom has a profile for this one. Try Dealroom → and named Kirsten Kester chief business officer and Sieun K. Barnes director of process development. The funding supports KR-402, the company's mRNA-encoded CAR-T candidate for follicular lymphoma. Kernal did not disclose the investment amount.

What's the endgame? Kernal is a Cambridge, Massachusetts TechBio company building in vivo cell therapies using AI-designed mRNA and targeted lipid nanoparticles. KR-402 aims to generate CAR-T cells directly in the body, potentially avoiding the costly ex vivo manufacturing that current therapies require.

Who are the hires? Kester joins from Obsidian Therapeutics, where she helped lead corporate strategy, financings, and partnerships, including a $350 million private placement and collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. Barnes brings process-development experience, a capability tied to manufacturing the program at scale.

Why now? The IFLI investment builds on an award of up to $48 million from the Advanced Research Projects Agency for Health (ARPA-H) for KR-402, plus support from NVIDIA, Microsoft, and Eli Lilly through the Lilly Gateway Labs accelerator. The money and hires fit the financing and manufacturing needs of advancing a preclinical program.

What they're saying: "We're honored to partner with IFLI to advance KR-402 toward the clinic," said Yusuf Erkul, co-founder and CEO. IFLI managing director David McCullagh said the platform could address "lengthy manufacturing timelines and treatment complexity."

The signal: In vivo CAR-T is drawing capital, with recent financings and deals at companies including Typewriter Therapeutics and Sail BiomedicinesDealroom has a profile for this one. Try Dealroom →. Kernal's news is early-stage validation — public and disease-focused backing plus targeted hires — not evidence that KR-402 has shown clinical efficacy.

Read more: markets.financialcontent.com

Image credit: Generated with Gemini

More top stories